

INFORMATION DISCLOSURE CITATION

FILE COPY

Att) Docket No. 4189,90/9-03000 Serial No. 08/383,676

Applic A Russian HAUPTMANN et al.

Filing Date:

February 1, 1995

Group


1814

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
Kee	4,289,690	09/15/81	Pestka et al.	360	112	
PI	4,560,649	12/24/85	Saxena et al.	435	7	
	4,578,335	03/25/86	Urdal et al.	435	68	
	4,609,546	09/02/86	Hiratani	424	83	
	4,789,658	12/06/88	Yoshimoto et al.	574	12_	
	4,902,502	02/20/90	Nitecki et al.	424	83	
	4,904,584	02/27/90	Shaw et al.	435	69.4	
	4,931,544	06/05/90	Katre et al.	530	351	
	4,935,233	06/19/90	Bell et al.	424	85.5	
	4,966,888	10/30/90	Saxena et al.	574	Э	
	5,089,261	02/18/92	Nitecki et al.	424	85,5	
	5,116,964	05/26/92	Capon et al.	536	27	
	5,136,021	08/04/92	Dembinski et al.	530	350	
	5,153,265	10/06/92	Shadle et al.	325	54.1	
	5,162,430	11/10/92	Rhee et al.	525	54.1	
	5,214,131	05/25/93	Sano et al.	530	345	
	5,252,714	10/12/93	Harris et al.	530	391.9	
	5,344,915	09/06/94	LeMaire et al.	530	350	
	5,359,037	10/25/94	Wallach et al.	530	388.12	
	5,382,657	01/17/95	Karasiewicz et al.	530	35	
	5,395,760	03/07/95	Smith et al.	435	240.1	
	5,478,925	12/26/95	Wallach et al.	530	351	
	5,512,544	04/30/96	Wallach et al.	514	12	
Kcc	5,610,279	03/11/97	Brockhaus et al.	530	387.3	

FOREIGN PATENT DOCUMENTS


	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
I'cc	EP 0 225 579 A3	06/16/87	Europe			




' AUG O	177						
Week Men		P 0 247 860 A2	12/02/87	Europe			
TAAD	EMAN	EP 0 259 863 A2	03/16/88	Europe			
Kee	_	EP 0 334 165 A2	09/27/89	Europe			
		DE 39 10 323 A1	10/19/89	Germany	حـــــ		
Kcc	-	EP 0 512 528 A2	11/11/92	Europe			
		DE 3913101.7	4-17-89	Germany			XX
		EP 0 393 438 A2	10/24/90	Europe			XX
		EP 0 398 327 A1	11/22/90	Europe			
Rec	۵	DE 03 920 282.	6-20-89	Germany			XX
		WO 90/13575	11/15/90	PCT			
		EP 0 417 563 A2	03/20/91	Europe	_		
ICCC		EP 0 418 014 A1	03/20/91	Europe	د		
1		EP 0 422 339	04/17/91	Europe			
= · ·		WO 91/03553	0 5 /21/91 °,	PCT	_		
		GB 2 246 569 A	02/05/92	Great Britain			
		WO 92/01474	02/06/92	PCT			
		WO 92/07076	04/30/92	PCT .			
		WO 92/15682	09/00/92	PCT			
		WO 92/16221	10/01/92	PCT			
		WO 92/13095	08/06/92	PCT			
		WO 94/06476	03/31/94	PCT	J		
		EP 0 526 905 A2	02/10/93	Europe	.,		
		EP 0 154 316 A2	09/11/85	Europe			
Kce		EP 0 154 316 B1	09/13/89	Europe			
	(OTHER DOCUMENTS (Includ	ing Author, ?	itle, Date, Pertinent F	Pages, Et	c.)	
ppe	•	Anderson et al., "Quantative Approach, Hawes et al. (ed.)			rbridizatio	n: A Pract	ical
	Baglioni et al., "Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa a Lymphoblastoid Cells Sensitive to Growth Inhibition," <i>J. Biol. Chem.</i> 260(25):13395-13397 (19						
		Bakouche et al., "Plasma Me Membrane Protein Possibly I					
		Beutler et al., "Passive Immu from Lethal Effect of Endotox			ecrosis Fa	actor Prote	ects Mice
pice		Bowie et al., "Deciphering the Substitutions," Science, 247:			lerance to	Amino A	cid




1 AUC 0 4 1007	,
3 KC-	rennan et al., Lancet, vol.2 (8657), pp. 244-247 (1989)
PADEMARY	Capaldi et al., "Changes in Order of Migration of Polypeptides in Complex III and Cytochrome <u>c</u> Oxidase under Different Conditions of SDS Polyacrylamide Gel Electrophoresis," <i>Biochem. & Biophys. Res. Comm.</i> 74(2):425-433 (1977).
	Carlino et al., "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF Proteins", J. Biol. Chem. 262(3):958-961 (1987).
	Colletti et al., "The Production of Tumor Necrosis Factor Alpha and the Development of a Pulmonary Capillary Injury Following Hepatic Ischemia/Reperfusion," <i>Transplantation</i> 49(2):268-272 (1990).
	Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor α Inhibitor," <i>Chemical Abstracts</i> 113(38760n):454 (1990).
	Dembic et al., "Two Human TNF Receptors Have Similar Extracellular, But Distinct Intracellular, Domain Sequences," <i>Cytokine</i> 2(4):231-237 (1990)
	Engelmann et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-Like Activity," <i>J. Biol. Chem.</i> 265(24):14497-14504 (1990).
	Evans et al., "The Steroid and Thyroid Hormone Receptor Superfamily," <i>Science</i> 240:889-895 (1988).
	Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," BioTechnology 8:343-346 (1990).
	Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor," <i>Molecular and Cell Biology</i> 11(6):3020-3026 (1991).
	Grizzard et al., "Affinity-Labeled Somatomedin-C Receptors and Binding Proteins From the Human Fetus," <i>J. Clin. Endocrinol. & Metab.</i> 58(3):535-543 (1984).
	Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of <i>In Vitro</i> and <i>In Vivo</i> Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in <i>E. Coli</i> ," <i>J. Cell. Biochem.Suppl.</i> . 15F:113 (1991).
	Hatakeyama et al., "Interleukin-2 Receptor β Chain Gene: Generation of Three Receptor Forms by Cloned Human α and β Chain cDNA's," <i>Science</i> 244:551-556 (1989).
	Hauser et al., "Cytokine Accumulations in CSF of Multiple Sclerosis Patients: Frequent Detection of Interleukin-1 and Tumor Necrosis Factor but not Interleukin-6," <i>Neurology</i> 40:1735-1739 (1990)
	Heller et al., "Complementary DNA Cloning of a Receptor for Tumor Necrosis Factor and Demonstration of a Shed Form of the Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 87:6151-6155 (1990).
	Hofman et al., "Tumor Necrosis Factor Identified in Multiple Sclerosis Brain," <i>J. Exp. Med.</i> 170:607-612 (1989).
	Israel et al., "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," <i>Immunol. Lett.</i> 12:217-224 (1986).
	Kasukabe et al., "Purification of a Novel Growth Inhibitory Factor for Partially Differentiated Myeloid Leukemic Cells," <i>J. Biol. Chem.</i> 263(11):5431-5435 (1988).
	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-8335 (1990).
icce	Lantz et al., "Characterization <i>In Vitro</i> of a Human Tumor Necrosis Factor-Binding Protein," <i>J. Clin Invest.</i> 86(5):1396-1402 (1990)



F KAC	Le et al., "Tumor Necrosis Factor and Interleukin 1: Cytokines with Multiple Overlapping Biologic Activities," Lab Investigation 56(3):234-248 (1987).
PADE!	et al., "Generation of cDNA Probes Directed by Amino Acid Sequence: Cloning of Urate Oxidase," <i>Science</i> 239:1288-1291 (1988).
	Lehmann et al., "Demonstration of Membrane Receptors for Human Natural and Recombinant ¹² Labeled Tumor Necrosis Factor on HeLa Cell Clones and Their Role in Tumor Cell Sensitivity," <i>Eur. J. Biochem.</i> 158:1-5 (1986).
	Liao et al., "Characterization of a Human Interleukin 1 Inhibitor," <i>J. Immunol.</i> 134(6):3882-3886 (1985).
	Liao et al., "Identification of a Specific Interleukin 1 Inhibitor in the Urine of Febrile Patients," <i>J. Exp. Med.</i> 159:126-136 (1984).
	Liblau et al., "Tumor Necrosis Factor-α and Disease Progression in Multiple Sclerosis," <i>New Eng</i> J. <i>Med.</i> 326(4):272-273 (1992).
	Lindvall et al., "Modulation of the Constitutive Gene Expression of the 55 KD Tumor Necrosis Factor Receptor in Hematopoietic Cells," <i>Biochem. & Biophys. Res. Comm.</i> 172(2)557-563 (1990).
	Loetscher et al., "Recombinant 55-kDa Tumor Necrosis Factor (TNF) Receptor," J. Biol. Chem. 266(27):18324-18329 (1991).
	March et al., "Cloning, Sequence and Expression of Two Distinct Human Interleukin-1 Complementary DNAs," <i>Nature</i> 315:641-647 (1985).
	Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," Tumor Necrosis Factor, (TNF) Receptor 56(2):305-317 (1987). (Abstract in English).
	Nexo et al., "Lectin-Agarose Immobilization, a New Method for Detecting Soluble Membrane Receptors," <i>J. Biol. Chem.</i> 254(18):8740-8743 (1979).
	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO J.</i> 9(10):3269-3278 (1990).
	Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," <i>J. Exp. Med.</i> 170:1409-1414 (1989)
	Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," <i>The Physiological and Pathological Effects of Cytokines</i> , pp. 413-421 (1990).
	Novick et al., "Purification of Soluble Cytokine Receptors from Normal Human Urine by Ligand-Affinity and Immunoaffinity Chromatography," <i>J. Chromatog.</i> 510:331-337 (1990).
	Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-1489 (1991).
	Piguet et al., "Tumor Necrosis Factor/Cachectin Plays a Key Role in Bleomycin-Induced Pneumopathy and Fibrosis," <i>J. Exp. Med.</i> 170:655-663 (1989).
	Powell et al., "Lymphotoxin and Tumor Necrosis Factor-alpha Production by Myelin basic Protein Specific T Cell Clones Correlates With Encephalitogenicity," <i>International Immunology</i> 2(6):539-544 (1990).
ccc	Rhein et al., "Another Sepsis Drug DownImmunex ¹ TNF Receptor," Biotechnology <i>Newswatch</i> pg. 1, 3(Monday, October 4, 1993).



MERAIN	
PADEMAN	Republe et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Perimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> 172:1193-1200 (1990).
FADEMAR	Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," <i>J. Exp. Med.</i> 167:1511-1516 (1988)
	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 α and 1 β But Not Tumor Necrosis Factor α ," <i>J. Immunol.</i> 139(5):1541-1545 (1987).
	Seckinger et al., "Characterization of a Tumor Necrosis Factor α (TNF-α) Inhibitor: Evidence of Immunological Cross-Reactivity with the TNF Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 87:5188-5192 (1990).
	Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity That Blocks Ligand Binding," <i>J. Immunol.</i> 139(5):1546-1549 (1987).
	Seckinger et la., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor α Inhibitor," <i>J. Biol. Chem.</i> 264(20):11966-11973 (1989)
	Selmaj et al., "Proliferation of Astrocytes In Vitro In Response to Cytokines: A Primary Role for Tumor Necrosis Factor," <i>J. Immunol.</i> 144(1):129-135 (1990).
	Selmaj et al., "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro," Annals of Neurology 23(4):339-346 (1988).
	Smith et al., "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>J. Biol. Chem.</i> 261(32):14871-14874 (1986).
	Spinas et al., "Induction of Plasma Inhibitors of Interleukin 1 and TNF-Alpha Activity by Endotoxin Administration to Normal Humans," <i>Am. J. Physiol.</i> 259:R993-R997 (1990).
	Suffys et al., "Involvement of a Serine Protease in Tumour-Necrosis-Factor-Mediated Cytotoxicity," <i>Eur. J. Biochem.</i> 178:257-265 (1988).
	Suggs et al., "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β2-Microglobulin," <i>Proc. Natl. Acad. Sci. USA</i> 78(11):6613-6617 (1981)
	The Cytokine Factsbook, Callard (ed.), Academic Press Inc., San Diego, CA., pp. 244-246 (1994).
	Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," <i>Nature</i> 330:662-664 (1987).
	Tracey et al., "Cachectin/Tumor Necrosis Factor Induces Cachexia, Anemia, and Inflammation," <i>J. Exp. Med.</i> 167:1211-1227 (1988).
	Tracey et al., "Metabolic Effects of Cachectin/Tumor Necrosis Factor Are Modified by Site of Production," <i>J. Clin. Invest.</i> 86:2014-2024 (1990).
	Tracey et al., "Physiological responses to cachectin," <i>Tumor necrosis factor and related cytotoxins. Wiley, Chichester (Ciba Foundation Symposium 131)</i> , pp. 88-108 (1987).
	Tsujimoto et al., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells," <i>Archives of Biochem. & Biophys.</i> 249(2):563-568 (1986).
	Unglaub et al., "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators," <i>J. Exp. Med.</i> 166:1788-1797 (1987).
pre	Vilcek et al., "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," <i>J. Cell. Physio. Supplement</i> 5:57-61 (1987).



PARTITION	Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Mustice Cell Types: Relationship to Function," Fed. Proc. 78th Annual meeting of the American Secty of Biological Chemists 46(6):2117 (1987).				
	Wallach et al., "Mechanisms Which Take Part in Regulation of the Response to Tumor Necrosis Factor," Lymphokine Research 8(3):359-363 (1989).				
	Wallach, David, "Preparations of Lymphotoxin Induce Resistance to Their Own Cytotoxic Effect," J. Immunol. 132(5):2464-2469 (1984).				
	Wallach et al., "Regulation of the Response to Tumor Necrosis Factor," Bonavida, Gifford, Kirchner, Old (eds), <i>Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg</i> 1987, pp. 134-147 (1988).				
	Walsh et al., "Isolation and Purification of ILS, an Interleukin 1 Inhibitor Produced by Human Gingival Epithelial Cells," <i>Clin. Exp. Immunol.</i> 68:366-374 (1987).				
	Weber et al., "Production of an Epidermal Growth Factor Receptor-Related Protein," <i>Science</i> 224:294297 (1984).				
	Yoshie et al., "Binding and Crosslinking of ¹²⁵ I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," <i>J. Biochem.</i> 100:531-541 (1986).				
Ica	Zeigler, Elizabeth J., "Tumor Necrosis Factor in Humans," New Engl. J. Med. 318(23):1533-1535 (1988).				
Examiner	Oshan Carbon Date Considered 9-9-917				
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
Form PTO 144	9 Patent and Trademark Office - U.S. Department of Commerce				